Genmab — Januar 2020

[AaBforever]

GENMAB/SYDBANK: DARZALEX-SALGET RUNDER 4 MIA. DOLLAR I 2020.

[AaBforever]

• Vi estimerer et markedssalg for Darzalex på 4144 mio. dollar i 2020

[E_L]

on teprotumumab - i read 'the company explained that the full course requires 23 vials, setting the cost at $343,000 wholesale acquisition cost' and in their presentation 'Expected average net realized price: ~$200,000' https://endpts.com/fda-hands-off-its-latest-whirlwind-drug-ok-as-horizon-hustles-would-be-blockbuster-to-the-market/

[E_L]

that is a big difference...

[E_L]

@AaBforever that is very close to what Danske had in october, 4146...

[StockBull]

But cash-burn will increase and no milestone payments so 2020 will be more or less same profit / bottom-line as 2019. So interesting who the marked will react

[StockBull]

who=how

[StockBull]

ESP around 35-36 kr per share for both 2019 and 2020

[StockBull]

so might be dead money next 6-9 month

[Helge_LarsenPI-redaktør]

Børsen: https://play.borsen.dk/social/5e280e57595ab4f00a338bd9

[kkjoel]

EL, hvordan skal man f
orstå "average net realised price".. er der fx rabatter? Og de taler i den forbindelse om ".. ex­pect a com­pli­ance rate of 75% to 80%." - har det med de 343.000 og 200.000 at gøre?

[E_L]

there will be rebates, there will be discounts and money paid to insurance and middle men, but i find it a very big difference

[E_L]

with the compliance rate i think they mean the number of patients that comply with that regimen, ie that follow through on the whole course as describe/ takes all the injections

[DevOp]

cd3/cd20 results + hopefully a "military style" deal and sc approval should provide for a little more than dead in the water, I hope...

[kkjoel]

Ja, sådan fremgik compliance jo osse af det der blev sagt på webcasten! Men jeg kom i tvivl, da de 343 vs 200 pludselig blev introduceret.

[kkjoel]

Og FØJ(!) for nogle rabatter. Mellemhandlersvin!!!

[kkjoel]

Ville De købe en brugt vogn af denne Mellemhandler...?!

[kkjoel]

Taksi - det vil jeg se. Følg efter den player!

[Helge_LarsenPI-redaktør]

Frank Hoerning Andersen

Investments | Client Advisory | Valuation | Financial Analysis | Communication | Equity Research | Healthcare Specialist
1d •

I believe Genmab should be a core holding in 2020. Genmab is much more than just Darzalex and investor focus should be on the strong pipeline. One of the most promising projects is Duobody-CD3xCD20 which has a great potential in hematological malignancies. Early data for treatment of lymphoma presented at ASH 2019 indicated a strong

[Helge_LarsenPI-redaktør]

efficacy and safety profile for Duobody-CD3xCD20.
These results could pave the way for a partnership deal in early 2020. I anticipate successful data could bring peak sales to around USD 3bn. With respect to Darzalex I believe the product will continue to deliver and drive peak sales further up. This is driven by larger impact from early lines of treatment, more patients getting treated with Darzalex and are living longer, and the likely approval of the subcutaneous formulation due in Q2’20.